KDOQI Update 2000


X. Biographical Sketches of the NKF-KDOQI Anemia Work Group Members

The following are brief sketches that describe the professional training and experience as well as principal business affiliations of the Work Group members. All Work Group members completed a disclosure statement certifying that any potential conflict of interest would not influence their judgement or actions concerning the NKF-KDOQI.

Joseph Eschbach, MD (Work Group Chair), is Clinical Professor of Medicine at the University of Washington in Seattle, Washington and a private practice nephrologist at Minor & James Medical in Seattle. Dr. Eschbach, who has been treating patients with chronic kidney disease and doing research for 37 years, served as Director of the first home dialysis training center in the United States. He has lectured extensively on the pathophysiology and treatment of the anemia of chronic kidney disease and has written more than 100 articles on the subject. Dr. Eschbach has received multiple awards for his efforts to improve the quality of life for dialysis patients, including the David M. Hume Memorial Award, National Kidney Foundation (1995), and the Haviland Award of Excellence, Northwest Kidney Foundation (1991). He is a member of the Institute of Medicine of the National Academy of Sciences (1990).

Peter DeOreo, MD, FACP (Work Group Vice-Chair), is Medical Director and Chief Medical Officer of the Centers for Dialysis Care, Cleveland, Ohio. He and 40 other nephrologists in the Cleveland area are working to improve clinical outcomes for 1,000 patients. Dr. DeOreo is an Associate Clinical Professor of Medicine at Case Western Reserve University and is a member of the Division of Nephrology of University Hospitals of Cleveland. He has served on the Medical Review Board of network 22, and was Chairman of the Ad Hoc Committee on Dialysis Adequacy for Network 9. Dr. DeOreo is a member of the External Monitoring Committee for National Cooperative Peritoneal Dialysis Adequacy Study, serves on the Health Status Outcomes in ESRD Working Group, and was a participant in the Institute of Medicine’s panel on measuring and managing quality in ESRD. He has published papers on quality improvement, care path development, dialysis adequacy, and patient-assessed functional health status measurement. Dr. DeOreo is an internist and consulting nephrologist for University MedNet.

John Adamson, MD, is currently the Executive Vice President for research and Director of the Blood Research Institute of the Blood Center of Southeastern Wisconsin in Milwaukee. He is also Professor (Hematology/Oncology) in the Department of Medicine at the Medical College of Wisconsin. Dr. Adamson received his M.D. degree from the University of California, Los Angeles. He then trained at the University of Washington, Seattle, and at the National Institutes of Health, Bethesda, Maryland, in the fields of internal medicine and hematology. Dr. Adamson is a Past President of the American Society of Hematology and the International Society for Experimental Hematology. In 1988, Dr. Adamson was designated a Clinical Research Professor of the American Cancer Society and elected Fellow, American Association for the Advancement of Science. He is the past Editor-in-Chief of Blood, past Editor of the Journal of Cellular Physiology and founding Editor of Current Opinion in Hematology. Altogether, he has authored or co-authored more than 400 scientific publications.

Jeffrey Berns, MD, FACP, is Associate Professor of Medicine at the University of Pennsylvania School of Medicine and Associate Chief of the Renal-Electrolyte & Hypertension Division at Presbyterian Medical Center of the University of Pennsylvania Health System in Philadelphia. Dr. Berns is a graduate of Case Western Reserve University School of Medicine and completed his Nephrology fellowship at Yale University. He has recently co-edited a book on renal aspects of HIV infection and is a co-editor of Drug Prescribing in Renal Failure, published by the American College of Physicians. Dr. Berns has published papers on a number of clinical topics including erythropoietin and iron treatment of anemia in dialysis patients, most recently on the effects of normal hematocrit levels on ambulatory blood pressures in hemodialysis patients, radiographic contrast-induced renal failure, and membranous nephropathy. He is involved in clinical research studies with erythropoietin, novel erythropoietic stimulating protein and iron gluconate in dialysis patients. He reported receiving research grant funding from Amgen, Inc. and R&D Laboratories, Inc. and has received lectureship honoraria from Schein Pharmaceuticals.

Geraldine Biddle, RN, CNN, is the President of Nephrology Nurse Consultants. She is a certified Nephrology Nurse who has worked in the field of renal dialysis for more than 30 years and has held clinical, administrative, and faculty positions at major academic centers in the Northeast. In 1988, she began to work as a consultant to the Network of New York and, in 1994, to the Center for Clinical Measurement and Improvement, HSQB, HCFA. She served as Chairperson for the ESRD Forum of Networks CQI Workgroup, and on behalf of the workgroup wrote the Guide for Improving the Quality of Care of Dialysis Patients, a central component of the National Anemia Cooperative project. She worked with the FDA on the production of the first in a series of videotapes produced by the agency to address user errors in dialysis. The video, Human Factors in Dialysis, later won the Commissioner’s Citation. Mrs. Biddle is a Certified Professional in Healthcare Quality and teaches quality management and CQI to dialysis staff at local, regional and national workshops. She is a former President of the American Nephrology Nurses’ Association, Immediate Past-President of the NKF of Northeast New York, and presently serves as President of the World Foundation for Renal Care. Mrs. Biddle is a consultant to the ESRD Network of New York, and the HCFA Office of Clinical Quality Management.

Thomas Comstock, PharmD, is Associate Professor, Department of Pharmacy and Pharmaceuticals, School of Pharmacy, and Department of Internal Medicine (Nephrology), School of Medicine, at Virginia Commonwealth University. Dr. Comstock has been active in the field of renal pharmacotherapy for 17 years. His teaching, research, and patient care activities focus on the pharmacokinetics and pharmacodynamics of drugs in patients with renal impairment, with the goal of improved patient outcomes. Recent areas of research include strategies for the optimization of therapy in the treatment of anemia, and antibiotic dosing strategies during hemodialysis. He has also guided protocol development for anemia management in affiliated dialysis centers. He is an active member of the American College of Clinical Pharmacy - Nephrology Practice Research Network and other pharmacy and nephrology organizations, and serves on the nephrology editorial panel for the Annals of Pharmacotherapy.

Kathy Jabs, MD, is the Director of Pediatric Nephrology at Vanderbilt University Medical Center and an Associate Professor of Pediatrics at Vanderbilt University School of Medicine, Nashville, TN. Dr. Jabs has had a long-standing interest in the care of children with chronic kidney disease. Her clinical and research interests have included evaluations of the outcomes of dialysis and transplantation in children as well as the factors contributing to morbidity in these children, such as anemia and growth retardation. Dr. Jabs has published and given invited lectures on these topics. She is currently a member of the Scientific Advisory Committee of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). Dr. Jabs is a member of the speaker’s bureau for Schein Pharmaceuticals.

J. Michael Lazarus, MD, is Senior Vice President of Clinical Quality and Medical Director of Fresenius Medical Care North America. Dr. Lazarus has been affiliated with Fresenius Medical Care North America (formerly National Medical Care, Inc.) for 25 years as a Medical Director and consultant. Dr. Lazarus is Vice Chairman of the Board of Directors of Renaissance Health Care Inc. and is on the Board of Directors of Optimal Health Care, Inc. Dr. Lazarus received his undergraduate degree from the University of North Carolina and his medical degree from Tulane University. His internship and residency training were at Emory University/Grady Hospital and Tulane University/ Charity Hospital. Dr. Lazarus completed his nephrology training at Harvard Medical School and the Peter Bent Brigham Hospital. Prior to assuming his present position at FMCNA in April, 1996, Dr. Lazarus was Director of Clinical Services in the Nephrology Division and Director of the Dialysis Unit at the Brigham and Women’s Hospital and continues to hold the position of Associate Professor of Medicine at Harvard Medical School.

Allen Nissenson, MD, is a Professor of Medicine at the University of California, Los Angeles, and Director of the Dialysis Program. After completing a 2-year fellowship in nephrology at Northwestern University Medical School, Dr. Nissenson was recruited to UCLA in 1977, where he developed a comprehensive dialysis program. Dr. Nissenson has served as Chair of the Southern California End Stage Renal Disease (ESRD) Network, and is currently Chair of the Medical Advisory Board of the NKF of Southern California. He has long been concerned with issues of healthcare delivery and has consulted for Rand Corporation on ESRD reimbursement and Baxter Healthcare Corporation on peritoneal dialysis. He is currently working with Renal management Strategies (RMS) and RMS Lifeline to develop renal disease management and outpatient vascular access care programs. Dr. Nissenson has served as Chair of the Quality Assurance Committee of the Forum of ESRD Networks, and the Council on Dialysis of the NKF, and is a member of the board and President of the Renal Physicians Association. He was a Robert Wood Johnson Health Policy Fellow of the Institute of Medicine, serving in the office of Senator Paul Wellstone. Dr. Nissenson is the author of numerous scientific papers related to clinical aspects of the care of dialysis patients, and is the editor of two dialysis textbooks. He was the founding editor-in-chief of Advances in Renal Replacement Therapy.

John Stivelman, MD, is Chief Medical Officer of the Northwest Kidney Centers, and Associate Professor of Medicine in the Division of Nephrology, Department of Medicine, at the University of Washington School of Medicine in Seattle. Dr. Stivelman has been involved in investigative efforts to optimize hematopoietic therapy for dialysis patients since recombinant erythropoietin was used in phase III human trials in 1986. His major interests center on iron utilization, mechanisms of resistance to erythropoietin therapy, and factors that improve dialytic survival of disadvantaged populations. Dr. Stivelman also serves as medical director of one of the Northwest Kidney Centers’ freestanding facilities. He has served previously as the chair of the Network 6 Medical Review Board, as a member of the Forum of Networks Board of Directors and CQI Committee, and the MKSAP for Nephrology.

David Van Wyck, MD, is Professor of Medicine and Surgery at the University of Arizona College of Medicine. He has an active Nephrology practice at Tucson Associates in Nephrology-Hypertension. An investigator for more than 25 years, he has published and spoken widely on anemia and anemia management in patients with chronic kidney disease. He has led or participated in sentinel clinical trials in his field, beginning with the US Phase III Epoetin alfa trials. He has served as Chief of the Renal Section at the Arizona Health Sciences Center, Medical Director of the University-affiliated Desert Dialysis Center, Chief of Medicine at the Tucson VA Medical Center, coordinator of medical student and residency training programs at the VA Medical Center, and is a member of the Arizona Kidney Foundation Medical Advisory Board.




© 2001 National Kidney Foundation, Inc

web version created by cyberNephrologyTM and The Nephron Information Center